RT Journal Article
SR Electronic
T1 PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1545
OP 1549
DO 10.2967/jnumed.120.259630
VO 62
IS 11
A1 Baratto, Lucia
A1 Song, Hong
A1 Duan, Heying
A1 Hatami, Negin
A1 Bagshaw, Hilary P.
A1 Buyyounouski, Mark
A1 Hancock, Steven
A1 Shah, Sumit
A1 Srinivas, Sandy
A1 Swift, Patrick
A1 Moradi, Farshad
A1 Davidzon, Guido
A1 Iagaru, Andrei
YR 2021
UL http://jnm.snmjournals.org/content/62/11/1545.abstract
AB Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor–targeting 68Ga-RM2 with the prostate-specific membrane antigen (PSMA)–targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients underwent both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 (n = 23) or 18F-DCFPyL (n = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUVmax was collected for all lesions. Results: 68Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. 68Ga-PSMA11/18F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: 68Ga-RM2 detected 7 more lesions in 4 patients, whereas 68Ga-PSMA11/18F-DCFPyL detected 36 more lesions in 13 patients. Conclusion: 68Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used 68Ga-PSMA11/18F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.